Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

Dec 11 (Reuters) - Eli Lilly said on Thursday its ‌next-generation ​obesity drug helped patients lose ‌an average of 28.7% of ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual stocks.

This comes just under a month after Pfizer finalised a deal to acquire Metsera following a bidding war with Novo Nordisk.

No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading ...

Important state and national stories, market and business news, sports and entertainment, delivered in quick-hit fashion ...

Fundamentals-wise, ASML remains well positioned for further upside in 2026. Management continues to guide for growth in 2026 as strong as that in 2025. Sell-side analyst forecasts call for sales and ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called ...

Northwell Health reports that "Ozempic face" describes the facial changes from rapid weight loss using Ozempic, highlighting ...